Diurnal variation of plasma protease inhibitor concentrations

AIDS

Volumn 16, Issue 18, 2002, Pages 2487-2489

  Justesen, Ulrik S ^a   Pedersen, Court ^b  

^a UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^b ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; INDINAVIR; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR;

ARTICLE; CIRCADIAN RHYTHM; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; HUMAN; PRIORITY JOURNAL; PROTEINASE INHIBITION; STEADY STATE;

CIRCADIAN RHYTHM; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; NELFINAVIR; RITONAVIR; SAQUINAVIR;

EID: 0037032931     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200212060-00019     Document Type: Article

References (5)

1. Burger DM, Hugen PW, Aarnoutse RE, Hoetelmans RM, on behalf of the ATHENA Study Group. Treatment failure of nelfinavir-containing triple therapy can largely be explained by low nelfinavir plasma concentrations. AIDS 2000; 14 (Suppl. 4):P258.
2. Gatti G, Di Biagio A, Casazza R, De Pascalis C, Bassetti M, Cruciani M, et al. The relationship between ritonavir plasma levels and side-effects: Implications for therapeutic drug monitoring. AIDS 1999; 13:2083-2089.
3. Baede-van Dijk PA, Hugen PW, Verweij-van Wissen CP, Koopmans PP, Burger DM, Hekster YA. Analysis of variation in plasma concentrations of nelfinavir and its active metabolite M8 in HIV-positive patients. AIDS 2001; 15:991-998.
4. Hsu A, Granneman GR, Witt G, Locke C, Denissen J, Molla A, et al. Multiple-dose pharmacokinetics of ritonavir in human immunodeficiency virus-infected subjects. Antimicrob Agents Chemother 1997; 41:898-905.
5. Aarnoutse R, Burger D, Verweij-Van Wissen C, Van Ewijk-Beneken Kolmer E, Wuis E, Hekster Y. An international interlaboratory quality control (QC) program for therapeutic drug monitoring (TDM) in HIV infection. In: 8th Conference on Retroviruses and Opportunistic Infections. Chicago, February 2001 [Abstract 734].